A New Era of Prostate Cancer Precision Medicine

Prostate cancer is the second most common male cancer affecting Western society. Despite substantial advances in the exploration of prostate cancer biomarkers and treatment strategies, men are over diagnosed with inert prostate cancer, while there is also a substantial mortality from the invasive di...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 9; p. 1263
Main Authors Malik, Adil, Srinivasan, Srilakshmi, Batra, Jyotsna
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 26.11.2019
Subjects
biomarkers
gene fusion
genome editing
Oncology
precision medicine
prostate cancer
proteomic technologies
genome editing
prostate cancer
biomarkers
gene fusion
precision medicine
proteomic technologies
non-coding genome
liquid biopsy
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer is the second most common male cancer affecting Western society. Despite substantial advances in the exploration of prostate cancer biomarkers and treatment strategies, men are over diagnosed with inert prostate cancer, while there is also a substantial mortality from the invasive disease. Precision medicine is the management of treatment profiles across different cancers predicting therapies for individual cancer patients. With strategies including individual genomic profiling and targeting specific cancer pathways, precision medicine for prostate cancer has the potential to impose changes in clinical practices. Some of the recent advances in prostate cancer precision medicine comprise targeting gene fusions, genome editing tools, non-coding RNA biomarkers, and the promise of liquid tumor profiling. In this review, we will discuss these recent scientific advances to scale up these approaches and endeavors to overcome clinical barriers for prostate cancer precision medicine.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Zhi Sheng, Virginia Tech, United States
Reviewed by: Marco A. Velasco-Velazquez, National Autonomous University of Mexico, Mexico; Robin T. Varghese, Edward via College of Osteopathic Medicine, United States
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2019.01263